NetraMark applies AI to clinical trial design through its NetraAI platform, targeting the decisions that determine whether a trial succeeds before a single patient is enrolled.
The named outputs are concrete: discovering optimal dosage, understanding which patient populations a treatment actually suits, and increasing effect size. That last one is the commercially significant claim – a treatment that works in a subpopulation can fail an undifferentiated trial entirely, and identifying that group in advance is the difference between a failed programme and an approved one. It also supports late-phase decision-making from existing trial data.
NetraMark is publicly traded (TSX: AIAI, OTCQB: AINMF, FRA: PF0), which is unusual in this catalogue and means its financials and filings are open to inspection. The evidence section carries publications, posters and white papers – appropriate for a clinical audience, and the right place to judge it. Engagement runs through the company rather than self-serve signup.
